Telmisartan

also known as Micardis · Pritor · BIBR 277 · Gliosartan · Kinzal · Kinzalmono · Predxal · Samertan · +21 more

Other / unclassified targets AGTR1, PPARG via inhibition / activation

Developed for: hypertensive disorder · essential hypertension · COVID-19 · diabetic kidney disease · type 2 diabetes mellitus · metabolic syndrome X · HIV infectious disease · hyperlipidemia, combined, 2
+41 more
· intracerebral hemorrhage · obesity disorder · Alzheimer disease · coronary atherosclerosis · schizoaffective disorder · schizophrenia · vascular dementia · acute coronary syndrome · acute graft versus host disease · acute myocardial infarction · adult acute respiratory distress syndrome · atherosclerotic cardiovascular disease · cardiovascular disorder · chemotherapy-induced neuropathy · congestive heart failure · diabetes mellitus · doxorubicin induced cardiomyopathy · glucose intolerance · heart disorder · NAFLD1 · neuropathy, painful · obstructive sleep apnea syndrome · ovarian cancer · panic disorder · Parkinson disease · pneumonia · post-traumatic stress disorder · prediabetes syndrome · prostate cancer · proteinuria · stroke disorder · abdominal aortic aneurysm · atrial fibrillation · autosomal dominant polycystic kidney disease · chronic kidney disease · coronary artery disorder · heart failure · hemorrhagic stroke · myocardial infarction · peripheral arterial disease · symptomatic heart failure
Investigated by: Boehringer Ingelheim · Chong Kun Dang Pharmaceutical · Yuhan Corporation · Bayer · IlDong Pharmaceutical Co Ltd · Jeil Pharmaceutical Co., Ltd.
+119 more
· The George Institute · University of Bordeaux · ANRS, Emerging Infectious Diseases · Addpharma Inc. · Asan Medical Center · Canadian Institutes of Health Research (CIHR) · George Medicines PTY Limited · HB BioTech, LLC · Heart and Stroke Foundation of Canada · National Institute of Neurological Disorders and Stroke (NINDS) · PACCI Program · SEARCH Research Foundation · THPharm Corp. · Third Military Medical University · Tyler J Curiel · University of British Columbia · University of California, Los Angeles · University of Hawaii · University of Sydney · Abraham Edgar Gracia-Ramos · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Alliance for International Medical Action · Alzheimer's Drug Discovery Foundation · Australian and New Zealand Intensive Care Research Centre · Barcelona Institute for Global Health · Berry Consultants · CTCA · California HIV/AIDS Research Program · Carlos R. Rojo, MD · Cedars-Sinai Medical Center · Centre Hospitalier Universitaire de Nice · Centre Muraz · Coordinación de Investigación en Salud, Mexico · Cure Parkinson's · Daewon Pharmaceutical Co., Ltd. · Dartmouth-Hitchcock Medical Center · DongKoo Bio & Pharma · Dr. Frank Behrens · Emory University · Facultad de Medicina, Universidad de Buenos Aires, UBA · First Affiliated Hospital Xi'an Jiaotong University · French National Institute of Health and Medical Research · Gatsby Foundation · GlaxoSmithKline · Global Coalition for Adaptive Research · Hackensack Meridian Health · Hamilton Health Sciences Corporation · Hanlim Pharm. Co., Ltd. · Heidelberg University · Huons Co., Ltd. · Intensive Care National Audit & Research Centre · Istituto Auxologico Italiano · Johann Wolfgang Goethe University Hospital · John Black Charitable Foundation · Johns Hopkins University · Korea University Anam Hospital · Kyoto Prefectural University of Medicine · Laboratorio Elea Phoenix S.A. · Linical Korea · Mario Negri Institute for Pharmacological Research · McMaster University · Medical Research Council · Medical Research Institute of New Zealand · Medical University of Graz · Medtronic · Michael J. Fox Foundation for Parkinson's Research · Michael Smith Foundation for Health Research · Montreal Clinical Research Institute · NVP Healthcare · Nanfang Hospital, Southern Medical University · Nat Intensive Care Surveillance - MORU · National Heart Foundation Hospital and Research Institute of Bangladesh · National Heart Foundation of Bangladesh · National Institute for Health Research, United Kingdom · all 125 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	MICARDIS	—	2009-10-16	fda.gov ↗
Approved	EU (EMA)	Pritor	—	1998-12-11	europa.eu ↗
Approved	US (FDA)	MICARDIS	—	1998-11-10	fda.gov ↗

Trials 186 · started per year

today

US approved 1998

EU approved 1998

19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT07588932	May 2026 → Dec 2027 expected	stroke disorder	Spaulding Rehabilitation Hospital	Recruiting	No outcome recorded
Phase 0	NCT04021550	May 2023 → Dec 2026	obstructive sleep apnea syndrome	University of British Columbia	Withdrawn	No outcome recorded
Phase 149 trials · 1 met primary
Phase 1	NCT07784608	Sep 2026 → Apr 2027 expected	—	Huons Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1	NCT06168487	Apr 2024 → Apr 2026 overdue	prostate cancer	Tyler J Curiel	Recruiting	No outcome recorded
Phase 1	NCT06063109	Oct → Nov 2023	hypertensive disorder, type 2 diabetes mellitus	THPharm Corp.	Completed	No outcome recorded
Phase 1	NCT03802526	Apr → Jul 2019	—	NVP Healthcare	Completed	No outcome recorded
Phase 1	NCT03707899	Dec 2018 → Feb 2019	hyperlipidemia, combined, 2	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03662620	Oct → Dec 2018	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT03586037	Jun → Aug 2018	hyperlipidemia, hypertensive disorder	Addpharma Inc.	Completed	No outcome recorded
Phase 1	NCT03438955	Feb → Jul 2018	hypertriglyceridemia	DongKoo Bio & Pharma	Unknown	No outcome recorded
Phase 1	NCT03247140	Jun → Aug 2017	hyperlipidemia, combined, 2	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03461081	May → Jul 2017	hyperlipidemia, combined, 2	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03116516	Apr → May 2017	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT03032315	Oct → Dec 2016	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT02951962	Aug → Sep 2016	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT02739672	Jan → Apr 2016	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT02933658	Nov 2015	—	Daewon Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02170246	Jan 2015 → Jun 2018	HIV infectious disease	Yale University	Completed	No outcome recorded
Phase 1	NCT02233218	Jul → Oct 2014	—	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT02152969	May → Aug 2014	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT02579356	May → Aug 2014	essential hypertension	Samil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03889145	Dec 2013 → Feb 2014	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01975961	Jul → Aug 2013	hyperlipidemia	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01842256	Apr → May 2013	essential hypertension, hyperlipidemia	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01842230	Apr → May 2013	essential hypertension, hyperlipidemia	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01992601	Nov → Dec 2012	—	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01356017	Jun → Sep 2011	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01356043	May → Aug 2011	—	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01352689	Apr → May 2011	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01340131	Jan → Mar 2011	essential hypertension	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01246193	Nov → Dec 2010	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01181011	Aug → Nov 2010	—	Boehringer Ingelheim	Completed	Met primary
Phase 1	NCT02261064	Dec 2008 → Feb 2009	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02276378	Jul → Aug 2008	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259803	Oct → Nov 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02214966	Oct → Dec 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259777	Sep → Nov 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259790	Jul → Aug 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02215005	Jun → Sep 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02194309	Sep → Dec 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259816	May → Aug 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02262793	May → Jul 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02262650	Apr → May 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02262780	Dec 2003 → Feb 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02262572	Apr → Aug 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02264158	Sep 2001 → Mar 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02187536	Apr → May 2000	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02187523	Oct → Dec 1999	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02203500	Oct 1998 → Jan 1999	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02176512	Sep → Oct 1998	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02218684	Sep → Nov 1998	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT07370506	Feb 2026 → Jan 2027 expected	breast cancer, doxorubicin induced cardiomyopathy	Tanta University	Not yet recruiting	No outcome recorded
Phase 1/2	NCT02471833	Apr 2015 → Apr 2022	Alzheimer disease	Emory University	Completed	No outcome recorded
Phase 218 trials · 1 met primary · 3 missed
Phase 2	NCT07499440	Jun 2026 → Sep 2027 expected	post-traumatic stress disorder	HB BioTech, LLC	Recruiting	No outcome recorded
Phase 2	NCT06815497	Jan 2026 → Apr 2027 expected	ovarian cancer	Tyler J Curiel	Recruiting	No outcome recorded
Phase 2	NCT06483789	Oct 2024 → Sep 2026	panic disorder	HB BioTech, LLC	Terminated	No outcome recorded
Phase 2	NCT04510662	Aug 2020 → May 2021	COVID-19, adult acute respiratory distress syndrome	Abraham Edgar Gracia-Ramos	Completed	No outcome recorded
Phase 2	NCT04360551	Jul 2020 → Apr 2022	COVID-19	University of Hawaii	Terminated	Missed primary
Phase 2	NCT05322889	Apr 2020 → Oct 2022	chemotherapy-induced neuropathy, neuropathy, painful	Dr. Frank Behrens	Completed	No outcome recorded
Phase 2	NCT03868839	Feb 2019 → Oct 2020	schizoaffective disorder, schizophrenia	Xiaoduo Fan	Terminated	No outcome recorded Stop: Business
Phase 2	NCT02750059	Jan 2015 → Feb 2018	—	SEARCH Research Foundation	Completed	No outcome recorded
Phase 2	NCT02085265	Mar 2014 → Feb 2025	Alzheimer disease	Sunnybrook Health Sciences Centre	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01928927	Jan 2014 → Mar 2016	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Missed primary
Phase 2	NCT01578772	Aug 2012 → Mar 2013	—	University of California, Los Angeles	Completed	Met primary
Phase 2	NCT01088295	May 2010 → Jun 2011	HIV infectious disease	University of California, Los Angeles	Completed	Missed primary
Phase 2	NCT01224860	Jan 2009 → Jun 2013	—	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 2	NCT02242344	Apr 2006 → Sep 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00146289	Feb → Oct 2005	obesity disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00153049	Jun 2004 → Jun 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02187484	Aug 1998 → Aug 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02187497	Jun → Sep 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/33 trials · 1 missed
Phase 2/3	NCT04920838	Apr 2021 → Aug 2023	COVID-19	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 2/3	NCT04466241	Nov 2020 → Nov 2021	COVID-19	ANRS, Emerging Infectious Diseases	Completed	Missed primary
Phase 2/3	NCT04356495	Jul 2020 → Oct 2021	COVID-19	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 356 trials · 12 met primary · 2 missed
Phase 3	NCT07207057	Sep 2025 → May 2031 expected	Parkinson disease	University College, London	Recruiting	No outcome recorded
Phase 3	NCT06647745	Apr 2025 → Jun 2026 overdue	hypertensive disorder, type 2 diabetes mellitus	THPharm Corp.	Recruiting	No outcome recorded
Phase 3	NCT04518293	Jul 2021 → Aug 2023	hypertensive disorder	George Medicines PTY Limited	Completed	Met primary
Phase 3	NCT04518306	Jun 2021 → Sep 2023	hypertensive disorder	George Medicines PTY Limited	Completed	Met primary
Phase 3	NCT04606563	Oct 2020 → Apr 2022	COVID-19	University of British Columbia	Terminated	Missed primary
Phase 3	NCT04659070	Jul 2020 → May 2022	essential hypertension, hyperlipoproteinemia	Hanlim Pharm. Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04359953	Apr 2020 → Apr 2022	COVID-19	University Hospital, Strasbourg, France	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03785067	Feb 2020 → Feb 2021	hypertensive disorder, intracerebral hemorrhage, vascular dementia	The George Institute	Terminated	No outcome recorded Stop: Business
Phase 3	NCT03872232	Feb 2019 → Aug 2020	essential hypertension, hyperlipoproteinemia	Addpharma Inc.	Completed	No outcome recorded
Phase 3	NCT02699645	Sep 2017 → Aug 2025	hypertensive disorder, intracerebral hemorrhage	The George Institute	Completed	Met primary
Phase 3	NCT03088254	Sep 2016 → Jul 2017	—	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	Mixed
Phase 3	NCT01983735	Jan → Aug 2014	hypertensive disorder	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 3	NCT01914432	Nov 2013 → Jun 2014	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	Met primary
Phase 3	NCT01911780	Jul 2013 → Jan 2015	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT02087540	May 2013 → Dec 2014	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 3	NCT01634295	Jul 2012 → May 2013	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01501253	Aug 2011 → Sep 2012	essential hypertension	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01202721	Jun 2011 → Apr 2016	heart disorder	Hamilton Health Sciences Corporation	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01204398	Nov 2010 → Jul 2011	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01222520	Oct 2010 → Jun 2011	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01103960	Jul 2010 → Aug 2011	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01134393	May 2010 → May 2011	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00877929	Feb 2009 → May 2010	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00624052	Mar 2008 → Jun 2009	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00618774	Jan 2008 → Oct 2009	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00614380	Jan 2008 → Mar 2009	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00553267	Nov 2007 → Oct 2008	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00550953	Oct 2007 → Jul 2008	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00558428	Oct 2007 → Sep 2008	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00558064	Oct 2007 → Sep 2008	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00738660	Feb 2007 → May 2008	diabetic kidney disease	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 3	NCT00452192	Nov 2006 → Dec 2009	metabolic syndrome X	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 3	NCT00208221	Aug 2006 → Jun 2007	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Montreal Clinical Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00326768	May 2006 → Aug 2007	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00281593	Apr 2006 → Apr 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00281580	Apr 2006 → Mar 2007	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00316095	Apr 2006 → Aug 2007	hyperlipidemia, hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00267943	Jan 2006 → Jan 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00146341	Apr 2005 → Sep 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00144222	Jan → Aug 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00147264	Apr 2004 → Jan 2006	metabolic syndrome X	McMaster University	Completed	Missed primary
Phase 3	NCT00133185	Mar 2004 → Mar 2005	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02206659	Aug 2000 → Feb 2001	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02269176	Jul 2000 → Jan 2001	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177500	Jan → May 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02175355	Oct 1999 → Aug 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177487	Jun 1999 → Jan 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177435	Feb → Sep 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02176499	Feb → Jul 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177448	Sep 1998 → Sep 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177422	Jun 1998 → Nov 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02183701	Apr → Dec 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177409	Apr → Dec 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177396	Apr → Dec 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274118	Jul 1997 → Jan 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded

Phase 446 trials · 4 met primary
Phase 4	NCT05843162	Jun → Dec 2023	essential hypertension, metabolic syndrome X	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 4	NCT06431477	Apr 2023 → Oct 2025	diabetic kidney disease, essential hypertension	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 4	NCT05155436	Jan 2022 → Mar 2023	hypertensive disorder, mineral metabolism disease	National Heart Foundation of Bangladesh	Completed	No outcome recorded
Phase 4	NCT04355936	May → Nov 2020	—	Laboratorio Elea Phoenix S.A.	Completed	Met primary
Phase 4	NCT03474562	Apr 2018 → Jun 2019	atherosclerotic cardiovascular disease, hypertensive disorder, prediabetes syndrome	Yuhan Corporation	Completed	No outcome recorded
Phase 4	NCT03504566	Nov 2017 → Jun 2019	diabetic kidney disease	Steno Diabetes Center Copenhagen	Withdrawn	No outcome recorded
Phase 4	NCT03319823	Oct 2017 → Feb 2019	hypertensive disorder	Cedars-Sinai Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT02968160	Oct 2016 → Feb 2018	metabolic syndrome X	Yuhan Corporation	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02213224	Aug 2014 → Sep 2016	NAFLD1	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT01830530	May → Sep 2012	hypertensive disorder	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT01271478	Aug 2009 → Dec 2010	end stage renal failure	Coordinación de Investigación en Salud, Mexico	Completed	No outcome recorded
Phase 4	NCT00926289	Jun 2009 → Apr 2010	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT01819220	Apr 2009 → Nov 2014	hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT00981526	Mar 2009 → May 2012	schizoaffective disorder, schizophrenia	University of Massachusetts, Worcester	Completed	No outcome recorded
Phase 4	NCT00847262	Jun → Dec 2008	diabetes mellitus, hypertensive disorder, obesity disorder	Third Military Medical University	Completed	No outcome recorded
Phase 4	NCT00538486	Feb 2008 → Jun 2009	hypertensive disorder, obesity disorder	Third Military Medical University	Completed	No outcome recorded
Phase 4	NCT00559286	Dec 2007 → Jan 2009	hypertensive disorder, type 2 diabetes mellitus	RWTH Aachen University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00750113	Oct 2007 → Jul 2009	hypertensive disorder	Bayer	Completed	No outcome recorded
Phase 4	NCT00242814	Nov 2005 → Mar 2007	hypertensive disorder, metabolic syndrome X	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00168779	Sep 2005 → Jul 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00407862	Jan 2005 → Jun 2006	glucose intolerance, hypertensive disorder	Medical University of Graz	Completed	No outcome recorded
Phase 4	NCT02242812	Sep 2003 → Oct 2004	hypertensive disorder	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT00240448	Sep 2003 → Jun 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00168857	Jul 2003 → Jun 2006	diabetic kidney disease, hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00153023	Apr 2003 → Dec 2005	diabetic kidney disease, essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00240422	Feb 2003 → Jul 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00239538	Jan 2003 → Dec 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00153088	Jan 2003 → Nov 2005	diabetic kidney disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00240474	Dec 2002 → Mar 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274599	Oct 2002 → Nov 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274612	Oct 2002 → Nov 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274638	Jul 2002 → Jul 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02261116	Apr → Aug 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274144	Dec 2001 → Mar 2004	coronary atherosclerosis, essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00153101	Nov 2001 → Jun 2008	cardiovascular disorder	Boehringer Ingelheim	Completed	Mixed
Phase 4	NCT00034840	Oct 2001 → Aug 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02242318	Sep 2001 → Sep 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274105	Mar 2001 → Oct 2004	coronary atherosclerosis, hypertensive disorder	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT02178306	Sep 2000 → Apr 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02200653	May 2000 → Feb 2001	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02177461	Apr 2000 → Aug 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02260089	Mar 2000 → Jul 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02200640	Mar → Dec 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02172586	Jan 2000 → Jan 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02242370	Sep 1999 → Nov 2000	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00490958	Jan 1999 → Jun 2005	congestive heart failure	University of Campania Luigi Vanvitelli	Completed	Met primary

Phase not applicable10 trials
—	NCT03956823	Aug 2019 → May 2021	essential hypertension	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
—	NCT05328310	Jan 2019 → Dec 2022	hypertensive disorder	Korea University Anam Hospital	Unknown	No outcome recorded
—	NCT03783754	Aug 2018 → Mar 2021	hypertensive disorder, intracerebral hemorrhage, vascular dementia	The George Institute	Terminated	No outcome recorded
—	NCT02768948	May 2017 → Sep 2019	diabetic kidney disease	Centre Hospitalier Universitaire de Nice	Completed	No outcome recorded
—	NCT02338232	Jul 2015 → Jan 2023	acute graft versus host disease	Hackensack Meridian Health	Terminated	No outcome recorded Stop: Enrollment
—	NCT02255253	Oct 2014 → Feb 2015	hypertensive disorder	The George Institute for Global Health, China	Completed	No outcome recorded
—	NCT00863980	Apr 2009 → Jul 2013	acute coronary syndrome, acute myocardial infarction, hypertensive disorder	Kyoto Prefectural University of Medicine	Terminated	No outcome recorded
—	NCT07652567	Jan 2007 → Apr 2026	hypertensive disorder	Qilu Hospital of Shandong University	Completed	No outcome recorded
—	NCT00185705	Oct 2006 → Jul 2007	hyperlipidemia, hypertensive disorder	Stanford University	Terminated	No outcome recorded
—	NCT00288717	Feb 2006 → Sep 2007	hypertensive disorder	Saitama Medical University	Unknown	No outcome recorded
Comparator or background therapy71 trials
Phase 1	NCT04667624 Comparator	Feb → Apr 2020	hypertensive disorder	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02608242 Comparator	Nov 2015 → Jun 2016	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Terminated	No outcome recorded Stop: Business
Phase 1	NCT02496910 Comparator	Jun → Sep 2015	hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT02358824 Comparator	Feb → May 2015	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT02250833 Comparator	Sep → Dec 2014	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT02183675 Comparator	Jul → Oct 2014	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01806363 Comparator	Nov 2012 → Jun 2013	hypertensive disorder	HanAll BioPharma Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01278797 Comparator	Jan → Feb 2011	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02209649 Comparator	Oct → Dec 1999	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT04715763 Comparator	Sep 2021 → Apr 2022	COVID-19	University of Hawaii	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04218552 Comparator	Feb 2020 → Feb 2021	essential hypertension	Addpharma Inc.	Completed	Met primary
Phase 2	NCT01128322 Comparator	Jul 2010 → Mar 2011	essential hypertension	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 2	NCT00939588 Comparator	Jul → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2/3	NCT00562952 Comparator	Nov 2007 → Dec 2011	coronary artery disorder, diabetes mellitus, heart failure	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT06348576 Comparator	May 2024 → Feb 2025	essential hypertension	Addpharma Inc.	Unknown	Met primary
Phase 3	NCT06052748 Comparator	Feb 2024 → Mar 2025	essential hypertension	Addpharma Inc.	Completed	Met primary
Phase 3	NCT04970108 Comparator	Aug 2023 → Jan 2025	hypertensive disorder, type 2 diabetes mellitus	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT05144360 Comparator	Aug 2022 → Jul 2024	hypertensive disorder, type 2 diabetes mellitus	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT04158076 Comparator	Jan 2020 → Jan 2021	essential hypertension, hyperlipoproteinemia	Addpharma Inc.	Completed	No outcome recorded
Phase 3	NCT03067688 Background	Apr 2017 → Mar 2018	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	Met primary
Phase 3	NCT03210532 Background	Oct 2016 → Sep 2017	hyperlipidemia, hypertensive disorder	Daewon Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02620163 Comparator	Dec 2015 → Dec 2016	essential hypertension	Yuhan Corporation	Completed	No outcome recorded
Phase 3	NCT03566316 Comparator	Nov 2015 → Jun 2017	hyperlipidemia, combined, 2	IlDong Pharmaceutical Co Ltd	Completed	Met primary
Phase 3	NCT02738632 Background	May 2015 → Aug 2016	essential hypertension	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT01975246 Comparator	Nov 2013 → Jun 2014	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01426100 Comparator	Aug 2011 → May 2012	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01286558 Comparator	Jan → Sep 2011	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00860262 Comparator	Mar → Dec 2009	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00560430 Comparator	Nov 2007 → Sep 2009	hypertensive disorder, hypertriglyceridemia, metabolic syndrome X	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 3	NCT01885559 Comparator	Jan 2006 → Jun 2014	autosomal dominant polycystic kidney disease	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00283686 Comparator	Jan 2006 → Jun 2014	autosomal dominant polycystic kidney disease	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00257491 Background	Nov 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00239369 Background	Oct 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00221845 Background	Jan 1998 → Jul 2007	chronic renal failure syndrome, congenital anomaly of kidney and urinary tract, hypertensive disorder, impaired renal function disease	Heidelberg University	Completed	No outcome recorded
Phase 4	NCT07547878 Comparator	Apr 2026 → Mar 2029 expected	chronic kidney disease, type 2 diabetes mellitus	Baylor Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT06041529 Comparator	Oct 2023 → Feb 2026 overdue	essential hypertension	Yuhan Corporation	Active not recruiting	No outcome recorded
Phase 4	NCT04394117 Comparator	Jun 2020 → Nov 2021	COVID-19	The George Institute	Completed	No outcome recorded
Phase 4	NCT04330300 Comparator	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded Stop: Business
Phase 4	NCT03860220 Comparator	Apr 2019 → Sep 2023	hyperlipidemia, hypertensive disorder	Hyo-Soo Kim	Completed	No outcome recorded
Phase 4	NCT03550859 Comparator	Jun 2018 → Dec 2021	chronic kidney disease, proteinuria	Yuhan Corporation	Unknown	No outcome recorded
Phase 4	NCT03267329 Comparator	Sep 2017 → Sep 2020	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 4	NCT04061824 Comparator	May 2016 → Dec 2018	hyperlipidemia, hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT03226340 Comparator	Dec 2015 → Mar 2018	essential hypertension	Seoul National University Bundang Hospital	Unknown	No outcome recorded
Phase 4	NCT02734355 Comparator	Nov 2015 → Jan 2016	atrial fibrillation	Research Institute for Complex Problems of Cardiovascular Diseases, Russia	Completed	No outcome recorded
Phase 4	NCT02373163 Comparator	Sep 2014 → Mar 2016	hypertensive disorder	Prevencion	Completed	No outcome recorded
Phase 4	NCT02231788 Comparator	Jun 2014 → Mar 2018	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	Met primary
Phase 4	NCT02079805 Comparator	Jun 2014 → Apr 2016	type 2 diabetes mellitus	Takeda	Completed	Missed primary
Phase 4	NCT01683084 Comparator	Sep 2012 → Nov 2018	abdominal aortic aneurysm	Palo Alto Veterans Institute for Research	Completed	No outcome recorded
Phase 4	NCT02057328 Comparator	Dec 2010 → Jan 2015	hypertensive disorder	Aristotle University Of Thessaloniki	Unknown	No outcome recorded
Phase 4	NCT01180205 Comparator	Aug 2010 → Oct 2011	hypertensive disorder	Johannes Gutenberg University Mainz	Unknown	No outcome recorded
Phase 4	NCT01377285 Background	Jun 2010 → Dec 2018	chronic renal failure syndrome	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT01541267 Comparator	Dec 2009 → May 2011	chronic kidney disease, proteinuria	Medical University of Gdansk	Completed	No outcome recorded
Phase 4	NCT01075698 Comparator	Jul 2009 → Feb 2015	hypertensive disorder	Kumamoto University	Completed	No outcome recorded
Phase 4	NCT00865020 Comparator	Mar 2009 → Jun 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00741585 Comparator	Sep 2008 → Jun 2018	chronic kidney disease, essential hypertension, stroke disorder	University of Vigo	Completed	No outcome recorded
Phase 4	NCT00702936 Comparator	Nov 2007 → Aug 2008	acute coronary syndrome, coronary artery disorder, myocardial infarction	Catholic University of the Sacred Heart	Unknown	No outcome recorded
Phase 4	NCT01011660 Comparator	Oct 2007 → Aug 2012	essential hypertension	Chinese Academy of Medical Sciences, Fuwai Hospital	Unknown	No outcome recorded
Phase 4	NCT00599885 Comparator	Sep 2007 → Jul 2008	coronary artery disorder, hypertensive disorder, type 2 diabetes mellitus	Korea University Anam Hospital	Completed	No outcome recorded
Phase 4	NCT00509470 Comparator	Jul 2007 → Jun 2012	essential hypertension	Tokyo University	Completed	No outcome recorded
Phase 4	NCT01435161 Comparator	May 2007 → Aug 2011	atrial fibrillation	The Second Affiliated Hospital of Chongqing Medical University	Completed	No outcome recorded
Phase 4	NCT00926341 Comparator	Oct 2006 → Jun 2008	metabolic syndrome X	Aligarh Muslim University	Completed	No outcome recorded
Phase 4	NCT00421863 Background	Feb 2005 → Jan 2009	hypertensive disorder	Heart Care Foundation	Completed	No outcome recorded
Phase 4	NCT00153062 Comparator	Aug 2003 → Apr 2008	stroke disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00295542 Comparator	Mar 2000 → Apr 2009	hypertensive disorder	University of Vigo	Completed	No outcome recorded
—	NCT07568574 Background	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT06515652 Comparator	Sep 2023 → Jul 2024 overdue	metabolic syndrome X	Hamdard University	Recruiting	No outcome recorded
—	NCT04736329 Comparator	Feb 2021 → Jul 2022	chronic kidney disease, symptomatic heart failure	Cairo University	Completed	No outcome recorded
—	NCT02593110 Comparator	Jan 2016 → May 2022	peripheral arterial disease	Northwestern University	Completed	No outcome recorded
—	NCT01996085 Comparator	Jan 2013 → Jun 2016	hypertensive disorder	Military Institute od Medicine National Research Institute	Completed	No outcome recorded
—	NCT01748253 Comparator	Nov 2012 → Oct 2013	atrial fibrillation	Acrobat Trial Group	Unknown	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 9

Date	Issuer	Release
2026-06-01	Chong Kun Dang Pharmaceutical	Results 종근당, 유럽고혈압학회서 '텔미누보 20/1.25mg' 3상 임상 결과 발표 ckdpharm.com ↗ 데이터에 따르면 텔미누보 20/1.25mg은 투약 8주 시점에서 수축기 혈압(msSBP)을 기저치 대비 17.6mmHg 감소시켜, 텔미사르탄 20mg 단일제(-14.15mmHg)와 에스암로디핀 1.25mg 단일제(-12.19mmHg) 대비 우수한 혈압강하 효과를 보였다.
2019-03-11	Jeil Pharmaceutical Co., Ltd.	Results 제일약품 "텔미듀오플러스"3제 복합제 임상 3상 결과 SCI급 국제학술지 게재 jeilpharm.co.kr ↗ 연구 결과 , 텔미사탄 / 암로디핀 / 로수바스타틴 투여군의 msSBP 는 베이스라인 대비 8 주 시점에서 24mmHg 감소 , 대조군 2 대비 15.mmHg ([95% CI, -21.78 to -8.43mmHg], P<0.001) 감소 효과를 보이며 고혈압 조절 효과의 탁월함을 입증했다 .
2017-02-15	Daiichi Sankyo	Regulatory Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha daiichisankyo.com ↗ Today, Daiichi Sankyo Espha obtained approval for manufacturing and marketing for multiple AG products, including the following products:
2016-09-28	Astellas Pharma Inc	Regulatory Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination- astellas.com ↗ announced that manufacturing and marketing approval for “Micatrio® Combination Tablets,” a combination of “Micardis® Tablets” (AT1 receptor blocker [ARB]), long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuretic hydrochlorothiazide (HCTZ) was obtained on September 28.
2015-09-23	IlDong Pharmaceutical Co Ltd	Regulatory 항고혈압, 고지혈증 3제복합제 TAR정 임상 3상 착수 ildong.com ↗ 일동제약(대표 이정치)이 항고혈압·고지혈 3제 복합제 TAR정(Telmisartan-Amlodipine-Rosuvastatin)에 대해 최근 식약처로부터 임상 3상을 승인받아, 이에 착수했다.
2012-12-21	Astellas Pharma Inc	Regulatory Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug astellas.com ↗
2010-06-13	Boehringer Ingelheim	Results Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 prnewswire.com ↗ Following rigorous assessment of the data from these studies it was concluded that there was no association with an increased risk of cancer in the telmisartan arms.
2010-02-26	Astellas Pharma Inc	Regulatory Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for "Micardis®Tablets", Angiotensin II receptor blocker astellas.com ↗ The decision for the withdrawal of application was made because currently submitted data is insufficient to establish an evidence that is necessary to attain the approval, as a result of discussion with Pharmaceutical and Medical Devices Agency.
2009-04-22	Astellas Pharma Inc	Regulatory MICOMBI® Combination Tablets approved for manufacturing and marketing astellas.com ↗ Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo: Chairman & President: Dr. Thomas Heil) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today that on 22 April the approval of manufacture and marketing of Micombi®Combination Tablets was obtained.

All press releases naming this drug 11 releases

Date	Issuer	Release
2026-06-01	Chong Kun Dang Pharmaceutical	종근당, 유럽고혈압학회서 '텔미누보 20/1.25mg' 3상 임상 결과 발표 ckdpharm.com ↗
2019-03-11	Jeil Pharmaceutical Co., Ltd.	제일약품 "텔미듀오플러스"3제 복합제 임상 3상 결과 SCI급 국제학술지 게재 jeilpharm.co.kr ↗
2017-10-30	Astellas Pharma Inc	Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family) astellas.com ↗
2017-02-15	Daiichi Sankyo	Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha daiichisankyo.com ↗
2016-09-28	Astellas Pharma Inc	Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination- astellas.com ↗
2015-09-23	IlDong Pharmaceutical Co Ltd	항고혈압, 고지혈증 3제복합제 TAR정 임상 3상 착수 ildong.com ↗
2012-12-21	Astellas Pharma Inc	Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug astellas.com ↗
2010-06-13	Boehringer Ingelheim	Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 prnewswire.com ↗
2010-02-26	Astellas Pharma Inc	Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for "Micardis®Tablets", Angiotensin II receptor blocker astellas.com ↗
2009-06-23	Astellas Pharma Inc	Combination Tablets commenced®Sales of Micombi -Telmisartan and HCTZ combination demonstrates potent hypertension reduction,broadening therapeutic options- astellas.com ↗
2009-04-22	Astellas Pharma Inc	MICOMBI® Combination Tablets approved for manufacturing and marketing astellas.com ↗

Evidence & citations 35 cited values

Every value below carries the sentence it was read from. 260 sources stand behind the page.

Field	Value	Cited text
Known as	Telmisartan	“One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ 250 “We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg,...” PMID 32937023 ↗ Sep 2020 “The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828 (Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.” NCT01340131 ↗ “In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.” NCT00221845 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin” NCT03116516 ↗ “telmisartan 40 mg/amlodipine 5 mg/rosuvastatin 10 mg (TEL/ALD/RSV) or amlodipine 5 mg/atorvastatin 10 mg (ALD/ATV) after washout/run-in period” PMID 38380420 ↗ Feb 2024 “The two HB-1 doses for this study include 64/192 and 86/258 telmisartan/verapamil extended release, using unique bi-layer tablets.” NCT07499440 ↗ “This study compared the CBP-lowering efficacies of nebivolol and telmisartan over a 12-week period in patients with hypertension.” PMID 40490940 ↗ Feb 2026 “FDC drug (80 mg of telmisartan and 20 mg of rosuvastatin); (2) 80 mg of telmisartan; (3) 20 mg of rosuvastatin; or (4) placebo.” PMID 29673890 ↗ Apr 2018 “Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily)” NCT00242814 ↗ Show 240 more sources
Known as	Bertel	“80 mg/12h of telmisartan (Bertel®, Laboratorio Elea Phoenix, Buenos Aires, Argentina) plus standard care or standard care alone will be monitored for development of systemic...” NCT04355936 ↗
Known as	BIBR 277	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02187484 ↗ 2 NCT02187497 ↗ NCT02177448 ↗
Known as	BIBR 277 SE	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	C09CA07	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Gliosartan	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 2 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗
Known as	Kinzal	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 2 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗
Known as	Kinzalmono	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 2 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗
Known as	Kinzalmono (previously telmisartan boehringer ingelheim pharma kg)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Micardis	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 28 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “Relative Bioavailability of Telmisartan in Micardis® and of Dipyridamole in Aggrenox® After Co-administration Compared to the Bioavailability of Telmisartan Respectively of...” NCT02262793 ↗ “Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension” NCT02242370 ↗ “Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily)” NCT02175355 ↗ “PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN” NCT00274599 ↗ “Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension” NCT00281580 ↗ “The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control” NCT00153088 ↗ “Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension” NCT00281593 ↗ “Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days” NCT04356495 ↗ “Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days” NCT04920838 ↗ Show 18 more sources
Known as	MICARDIS (Telmisartan)	“MICARDIS® (Telmisartan)” NCT01180205 ↗
Known as	Predxal	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 2 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗
Known as	Pritor	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 3 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗ NCT03438955 ↗
Known as	Samertan	“The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis,...” NCT00144222 ↗ 2 “The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN)...” NCT00168857 ↗ “evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.” NCT00153088 ↗
Known as	Semintra	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan actavis	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of kinzalkomb	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of micardis hct	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of micardisplus	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of onduarp	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of pritorplus	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of tolucombi	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan component of twynsta	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan teva	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan teva pharma	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Known as	Telmisartan/HCTZ FDC	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02187523 ↗
Known as	Telmitrend	“Telmitrend®Tab.(Telmisartan) 80mg” NCT02231788 ↗
Known as	Telmitrend Tab.	“Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg” NCT05843162 ↗
Known as	THP-00102	“THP-00102 (Telmisartan) 80mg” NCT06063109 ↗
Known as	Tolura	ChEMBL registry synonym — accepted as the source's own label CHEMBL1017 ↗
Action	Inhibit	“angiotensin II type 1 (AT-1) receptor blocker telmisartan” PMID 23731019 ↗ Jun 2013 1 “Type-1 angiotensin II receptor antagonist” CHEMBL1017 ↗
Modality	Other / unclassified	“Telmisartan is an angiotensin-II-type-1-receptor antagonist” NCT00407862 ↗
Route	Oral	“MICARDIS® (Telmisartan 80 mg p.o. Once Daily)” NCT00034840 ↗
Target	AGTR1	“Type-1 angiotensin II receptor antagonist” CHEMBL1017 ↗
Target	PPARG	“partial agonist properties to the PPARγ receptor” NCT00452192 ↗